

SEP 22 2006

**510(k) Summary for  
Dimension Vista™ C3 Flex® reagent cartridge  
Dimension Vista™ C4 Flex® reagent cartridge  
Dimension Vista™ Protein 1 Calibrator  
Dimension Vista™ Protein 1 Control L/M/H**

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SDMA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: 061852

**1. Manufacturer's Name, Address, Telephone, and Contact Person, Date of Preparation:**

Manufacturer: Dade Behring Marburg GmbH  
Emil-von-Behring Str. 76  
D-35001  
Marburg, Germany

Contact Information: Dade Behring Inc.  
P.O. Box 6101  
Newark, Delaware 19714-6101  
Attn: Kathleen Dray-Lyons  
Tel: 781-826-4551  
Fax: 781-826-2497

Preparation date: June 29, 2006

- 2. Device Name:** Dimension Vista™ C3 Complement Flex® reagent cartridge (C3)  
Dimension Vista™ C4 Complement Flex® reagent cartridge (C4)  
Dimension Vista™ Protein 1 Calibrator  
Dimension Vista™ Protein 1 Control L  
Dimension Vista™ Protein 1 Control M  
Dimension Vista™ Protein 1 Control H

**Classification:** Class II; Class II; Class II; Class I

**Product Code:** CZW; DBI; JIX; JJY

**Panel:** Immunology (82) and Clinical Chemistry (75)

**3. Identification of the Legally Marketed Device:**

Dade Behring N Antisera to Human Complement Factors (C3c, C4) - ~~K0124700~~  
Dade Behring N Protein Standard SL - K012470  
Dade Behring N/T Protein Control SL - K012468

050665

**4. Device Description:**

**Dimension Vista™ C3 and C4 Flex® reagent cartridges**

Proteins contained in human body fluids form immune complexes in an immunochemical reaction with specific antibodies. These complexes scatter a beam of light passed through the sample. The intensity of the scattered light is proportional to the concentration of the respective protein in the sample. The result is evaluated by comparison with a calibrator of known concentration.

**Dimension Vista™ Protein 1 Calibrator**

Protein 1 Calibrator is a multi-analyte, liquid human serum based product containing, C3 Complement, C4 Complement, Immunoglobulin A, Immunoglobulin G and Immunoglobulin M (IGM).

**Dimension Vista™ Protein 1 Controls L/M/H**

Protein 1 Controls L/M/H are multi-analyte, liquid human serum based products containing C3 Complement, C4 Complement, Immunoglobulin A, Immunoglobulin G and Immunoglobulin M (IGM).

**5. Device Intended Use:**

**Dimension Vista™ C3 Flex® Reagent Cartridge:**

The C3 method is an *in vitro* diagnostic test for the quantitative measurement of complement C3 in human serum and heparinized plasma on the Dimension Vista™ System. Measurements of C3 are used as an aid in the diagnosis of immunologic disorders associated with complement C3 protein.

**Dimension Vista™ C4 Flex® Reagent Cartridge:**

The C4 method is an *in vitro* diagnostic test for the quantitative measurement of complement C4 in human serum and heparinized plasma on the Dimension Vista™ System. Measurements of C4 are used as an aid in the diagnosis of immunologic disorders associated with complement C4 protein.

**Dimension Vista™ Protein 1 Calibrator:**

Protein 1 Calibrator is an *in vitro* diagnostic product for the calibration of C3 Complement (C3), C4 Complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG) and Immunoglobulin M (IGM) methods on the Dimension Vista™ System.

**Dimension Vista™ Protein 1 Control L/M/H:**

Protein 1 Controls L/M/H are for use as an assayed intralaboratory quality controls for the assessment of precision and analytical bias in determination of C3 Complement (C3), C4 Complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG) and Immunoglobulin M (IGM) on the Dimension Vista™ System.

**6. Medical device to which equivalence is claimed and comparison information:**

The Dimension Vista™ C3 and C4 Flex reagent cartridge, Dimension Vista™ Protein 1 Calibrator (K051087) and Dimension Vista™ Protein 1 Control L/M/H (K051087) are substantially equivalent to the Dade Behring N Antisera to Human Complement Factors (C3c, C4) assays (K050665), N Protein Standard SL (K012470) and N/T Protein Control SL (K012468), respectively. The Dimension Vista™ C3 and C4 assays, like the N Antisera to Human Complement Factors (C3c, C4) assays are *in vitro* diagnostic reagents



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

SEP 22 2006

Dade Behring, Inc.  
c/o Ms. Kathleen Dray-Lyons  
Regulatory Affairs and Compliance Manager  
Glasgow Site  
P.O. Box 6101  
Newark, DE 19714

Re: k061852

Trade/Device Name: Dimension Vista™ C3 Flex® reagent cartridge  
Dimension Vista™ C4 Flex® reagent cartridge  
Dimension Vista™ Protein 1 Calibrator  
Dimension Vista™ Protein 1 Control L, Dimension Vista™ Protein 1  
Control M and Dimension Vista™ Protein 1 Control H

Regulation Number: 21 CFR 866.5240

Regulation Name: Complement Components Immunological Test System

Regulatory Class: Class II

Product Code: CZW, DBI, JIX, JJY

Dated: June 29, 2006

Received: June 30, 2006

Dear Ms. Dray-Lyons:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807);


Page 2 –

labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Robert L. Becker, Jr.", is written over a horizontal line.

Robert L. Becker, Jr., M.D., Ph.D.

Director

Division of Immunology and Hematology Devices

Office of In Vitro Diagnostic Device Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

## Indications Statement

**Device Name:**      **Dimension Vista™ C3 Flex® reagent cartridge**  
                         **Dimension Vista™ C4 Flex® reagent cartridge**  
                         **Dimension Vista™ Protein 1 Calibrator**  
                         **Dimension Vista™ Protein 1 Control L**  
                         **Dimension Vista™ Protein 1 Control M**  
                         **Dimension Vista™ Protein 1 Control H**

### Indications for Use:

#### **Dimension Vista™ C3 Flex® reagent cartridge:**

The C3 method is an *in vitro* diagnostic test for the quantitative measurement of complement C3 in human serum and heparinized plasma on the Dimension Vista™ System. Measurements of C3 are used as an aid in the diagnosis of immunologic disorders associated with complement C3 protein.

#### **Dimension Vista™ C4 Flex® reagent cartridge:**

The C4 method is an *in vitro* diagnostic test for the quantitative measurement of complement C4 in human serum and heparinized plasma on the Dimension Vista™ System. Measurements of C4 are used as an aid in the diagnosis of immunologic disorders associated with complement C4 protein.

#### **Dimension Vista™ Protein 1 Calibrator:**

Protein 1 Calibrator is an *in vitro* diagnostic product for the calibration of the C3 Complement (C3), C4 Complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), and Immunoglobulin M (IGM) on the Dimension Vista™ System.

#### **Dimension Vista™ Protein 1 Control L, Dimension Vista™ Protein 1 Control M and Dimension Vista™ Protein 1 Control H:**

Protein 1 Control L/M/H are for use as an assayed intralaboratory quality controls for the assessment of precision and analytical bias in determination of C3 Complement (C3), C4 Complement (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG) and Immunoglobulin M (IGM) methods on the Dimension Vista™ System.

Prescription Use   X    
(Per 21 CFR 801 Subpart D)

Over-The-Counter-Use \_\_\_\_\_  
(21 CFR 801)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

  
\_\_\_\_\_  
Division Sign-Off

Page 1 of \_\_\_\_

Office of In Vitro Diagnostic  
Device Evaluation and Safety

510(k)   K061852